Search
+
    SEARCHED FOR:

    MERCK

    Sun Pharma eyes $4 billion loan for Organon buy, five banks likely to anchor refinancing

    Sun Pharmaceutical Industries is gearing up to secure a substantial $4 billion syndicated loan aimed at refining its financial structure. This initiative is focused on refinancing a portion of the bridge financing used for its acquisition of Organon & Co. The company has recruited five lead arrangers to finalize the loan's terms.

    European stocks hit record highs on strong earnings, lower oil prices

    European stocks hit fresh record highs, supported by strong corporate earnings, easing geopolitical tensions and lower oil prices. The region's limited exposure to AI-linked stocks has also helped it outperform US equities amid concerns over technology valuations.

    His grandfather died of pancreatic cancer: This Hyderabad startup founder is using AI to develop a personalised cancer vaccines

    Hyderabad-based biotech startup PopVax, founded by Soham Sankaran, is developing AI-powered personalised cancer vaccines using mRNA technology. Inspired partly by his family's experience with pancreatic cancer, he aims to help the immune system identify and attack cancer cells using treatments designed around individual patients' tumour genetics.

    US Stock Market today: Why are S&P 500, Dow Jones, Nasdaq down? Check top and worst performing stocks at Wall Street

    Wall Street today saw one of the shocking losses as Google-parent Alphabet sufferedthe worst day since the company began trading at the US Stock Market.

    US Markets Today: US stocks end lower as Alphabet revenue miss revives AI capex jitters

    Wall Street ended the day on a sour note, as Alphabet's revenue shortfall cast a shadow over the AI investment landscape and overall market stability. The Nasdaq Composite was hardest hit, plummeting by 1.36 percent. Although the economy shows robust growth, investor focus shifted to inflation numbers and corporate profitability, which displayed resilience.

    Cipla sets sights on first-wave gains from rollout of Keytruda Biosimilar

    Cipla has partnered with Qilu Pharmaceutical to commercialize a biosimilar of Keytruda, which is a major cancer treatment. The patent for this drug is expected to expire around 2029, allowing for potential market entry. Cipla anticipates capturing a significant share of this lucrative market segment after the launch. Additionally, the company reported a 35% decline in consolidated net profit in the September quarter.

    • Moderna stock crashes 25%, loses about $24 billion after cancer vaccine data leak

      Moderna’s stock price dropped over 25% after trial results for its personalized melanoma vaccine with Merck were disclosed. The decline erased approximately $24 billion from Moderna’s market value, ending a significant rally this year. Analysts noted that this reaction was expected as investors often sell after news becomes public. Despite the drop, the trial results showed promising reductions in cancer recurrence when paired with Merck's Keytruda.

      US targets $500 billion India trade in 3 years, up from record $240 billion, Sergio Gor says

      The United States plans to increase bilateral trade with India to over USD 500 billion in three years. This trade target comes after reaching a record USD 240 billion, highlighting growing economic ties. Collaboration will focus on sectors like semiconductors, energy, and defense to foster mutual interests. Recent diplomatic engagements have already begun shaping a strategic alignment for both nations.

      Sun Pharma to raise Rs 10,000 crore to part-finance Organon deal

      Sun Pharmaceutical Industries plans to raise ₹10,000 crore through two tranches of rupee-denominated bonds. The funds will help refinance bridge loans taken for the Organon acquisition valued at $11.75 billion. The first tranche will amount to ₹7,000 crore with a coupon rate of 8.20%. Institutional investors are expected to participate, including notable companies like SBI Pension Fund and ICICI Prudential Mutual Fund.

      US stocks today: US stocks end higher as healthcare stocks lift Dow, tech a breather

      Wall Street ended higher on Tuesday, led by the Dow as investors shifted towards healthcare and other value stocks. The S&P 500 also gained, while the Nasdaq slipped as technology stocks paused after a rebound in the previous session. Healthcare shares gained, while small-caps and defensive sectors also outperformed.

      Zydus moves closer to US market for Keytruda biosimilar as FDA accepts application

      Zydus Lifesciences has received acceptance for its application regarding the biosimilar of Keytruda, which is a major cancer drug. The USFDA is expected to complete its review process by the third quarter of 2027. This biosimilar, named FYB206, was developed without a comparative Phase III efficacy trial. Zydus aims to make effective treatments more accessible in the oncology field in North America.

      It’s safety first for gas suppliers at Semicon Inc

      Suppliers want detailed guidelines from the Petroleum and Explosives Safety Organisation (PESO), without which they believe commercial hubs face heightened risk of leaks, fires and process disruption.

      Domestic demand, labour supply give India structural advantage in semiconductor push: Bain & Co

      India's strong domestic demand and demographic dividend give it an advantage in the global semiconductor race, but access to core technology remains a key hurdle, said Balaji Thirumalai, Partner and India Head of Semiconductors and Electronics Manufacturing Practice at Bain & Company. He said Semicon 2.0's focus on talent, fabs, OSATs, design, equipment and materials is needed to build a complete ecosystem.

      India's chip gains a democratic shield for global supply chains: PM at Semicon India 2026

      PM launches chip packaging facilities of Suchi Semicon in Gujarat, and CDIL in Punjab

      PM Modi asks semiconductor CEOs to step up industry participation in next phase of India’s growth

      Prime Minister Narendra Modi urged India to lead in emerging technologies. He assured industry leaders of a predictable and responsive policy environment. The government is committed to fostering innovation and skilling for future growth. CEOs expressed confidence in India's semiconductor sector potential. They pledged contributions to making India a global technology hub.

      JM Financial sees up to 28% upside in Dr Reddy’s and Aurobindo Pharma. Should you buy?

      JM Financial retained Buy ratings on Dr Reddy’s Laboratories and Aurobindo Pharma, seeing up to 28% upside over the next 12 months. The brokerage expects stronger earnings growth, business diversification and new product launches to support both drugmakers.

      Lupin gets USFDA approval for Modafinil tablets to treat excessive sleepiness

      Pharmaceutical major Lupin announced its USFDA approval for Modafinil tablets. These tablets are used to treat excessive sleepiness in adult patients. The approved drug is bioequivalent to Provigil Tablets of Nuvo Pharmaceuticals. Modafinil tablets had estimated annual sales of USD 70.7 million in the United States. Lupin currently operates 15 manufacturing facilities globally.

      Cipla, China's Qilu partner for US launch of Merck's Keytruda biosimilar

      Cipla said its US unit has entered an exclusive partnership with China’s Qilu Pharmaceutical to license QL2107, a biosimilar of Merck’s cancer drug Keytruda. Qilu will handle development, approvals, manufacturing and supply, while Cipla USA will commercialise the treatment in the US, as Cipla expands its oncology biosimilars portfolio.

      Tata, Merck explore exclusive chemical deal for Dholera semiconductor facility

      Tata Electronics is in discussions with Merck for an exclusive long-term agreement, potentially securing a primary supplier for specialty chemicals at its Dholera semiconductor facility. This collaboration aims to ensure a stable supply chain, crucial for India's burgeoning semiconductor industry.

      Verona Pharma stock jumps 20% on $10B Merck deal—can FDA-approved Ohtuvayre reshape COPD care?

      Verona Pharma stock jumped 20% after Merck announced it will acquire the British biotech in a $10 billion deal. Merck will pay $107 per share for Verona, following FDA approval of Verona’s COPD drug Ohtuvayre in June 2024. This move expands Merck’s respiratory pipeline as the company aims to strengthen its presence in the chronic obstructive pulmonary disease market. The deal is set to close in Q4 2025, pending UK regulatory approval. Investors are watching closely as this acquisition could reshape COPD treatment and boost Merck’s cardio-pulmonary drug portfolio long term.

      Dhananjay Singh takes over as Merck Life Science India MD

      In his role as the managing director, Singh will be responsible for driving the life science strategy in India, ensuring governance and compliance alongside other leaders from Merck's businesses in India. He joined Sigma-Aldrich in 1997. Over the years he took on several leadership roles in commercial organisations before his appointment as head of science and lab solutions commercial for India, a position he held since 2022.

      Final US hurdle for Merck's COVID-19 pill: FDA panel review

      If authorized, Merck's pill would be the first that U.S. patients could take at home to ease symptoms and speed recovery, a major step toward reducing hospital case loads and deaths. The drug, molnupiravir, is already authorized for emergency use in the U.K.

      P&G proposal for stake acquisition in company gets govt nod: Merck Ltd

      Govt has approved the proposal of P&G Overseas India BV for acquisition of up to 77.80 per cent of the paid-up equity share capital of the company, Merck Ltd said in a filing to BSE.

      Merck appoints Milind Thatte as MD

      He heads the leadership team of healthcare sector and is the member of the country council of Merck India, it added.

      Going against the grain: With the unique hybrid model for India, co aims at building scale & ramping up businesses.

      German Pharma firm Merck to shut down Bangalore GeNei

      Merck KGaA has decided to close down Bangalore GeNei, a company it had acquired in 2009 to bolster capabilities in design and production of biological research products.

      Merck's attempt to re-appoint board may face resistance from shareholders

      Merck is holding an AGM on April 8 and is seeking to re-appoint directors on its board but has nowhere mentioned in its notice to shareholders.

      Merck Ltd said its net profit declined by 4.49 per cent to Rs 17.62 crore for the quarter ended June 30, 2011, over the same period previous fiscal.

      Drug maker Merck Ltd on Tuesday posted 3.5 per cent decline in net profit to Rs 63.17 crore for the year-ended December 31, 2010.

      Load More
    The Economic Times
    BACK TO TOP